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ABSTRACT 
Objective: Systemic sclerosis (SSc) is a fibrotic immune-mediated disease of unknown 
etiology. Among its clinical manifestations, pulmonary involvement is the leading cause of 
mortality in SSc patients. However, the genetic factors involved in lung complication are not 
well-defined. We aimed to revisit the association of the MIF gene, which encodes a cytokine 
implicated in idiopathic pulmonary hypertension among other diseases, with the susceptibility 
and clinical expression of SSc, besides testing the association of this polymorphism with SSc-
related pulmonary involvement. 
Methods: A total of 4,392 SSc patients and 16,591 unaffected controls from six cohorts of 
European origin were genotyped for the MIF promoter variant rs755622. An inverse variance 
method was used to meta-analyze the data. 
Results: A statistically significant increase of the MIF rs755622*C allele frequency compared 
to controls was observed in the subgroups of patients with diffuse cutaneous SSc (dcSSc) and 
with pulmonary arterial hypertension (PAH) independently (dcSSc:P=3.20E-2, OR=1.13; 
PAH:P=2.19E-02, OR=1.32). However, our data revealed a stronger effect size with the subset 
of SSc patients showing both clinical manifestations (dcSSc with PAH:P=6.91E-3, OR=2.05). 
Conclusions: We revisited the association of the MIF rs755622*C allele with SSc and 
described a phenotype-specific association of this variant with the susceptibility to develop 
PAH in dSSc patients. 
KEY WORDS 
Systemic sclerosis, MIF, rs755622, Pulmonary arterial hypertension.  
MIF in Scleroderma-PAH 
 
4 
INTRODUCTION  
Systemic sclerosis (SSc) is a complex disease of unknown etiology influenced by both 
genetic and environmental factors. It is characterized by a progressive tissue fibrosis along 
with vascular anomalies and dysfunction, and the presence of auto-antibodies directed to 
different cellular structures, mainly anti-topoisomerase (ATA) and anti-centromere 
(ACA)antibodies. Depending on the extent of the skin implication, SSc is classified as diffuse 
cutaneous SSc (dcSSc) or limited cutaneous SSc (lcSSc). Among the clinical manifestations, 
pulmonary fibrosis (PF) and pulmonary arterial hypertension (PAH) are the leading cause of 
death in SSc patients [1]. These pulmonary complications can be present separately, as either 
interstitial lung disease (ILD) or isolated PAH, or combined [2].  
During the last years, great advances have been made in the determination of the genetic 
component of SSc [3, 4]. Nevertheless, we are still far from its complete understanding, 
especially with regard to pulmonary involvement, in which only few associated genes have 
been described [3,4]. 
Macrophage migration inhibitory factor (MIF) gene encodes a constitutively expressed 
protein that seems to have an important role on autoimmune and inflammatory processes. 
Infections, pro-inflammatory cytokines and antigen-specific activation can also lead to an 
increased expression of MIF [5,6]. The promoter region of this gene contains a single 
nucleotide polymorphism (SNP) at position -173 (rs755622) that has been associated with 
several immune-mediated diseases, including SSc and systemic lupus erythematosus (SLE) [7-
9]. This  SNP is in high linkage disequilibrium (LD) with a functional polymorphism, a -794 CATT 
(5-8) microsatellite repeat (rs5844572), also located at the promoter region of the gene [10]. 
Interestingly, increased MIF protein levels have been reported in patients with idiopathic 
pulmonary fibrosis, pulmonary hypertension, and in individuals affected by SSc-associated PAH 
[11-13]. 
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In the present study, we have analyzed for the first time the possible involvement of the 
MIF rs755622 polymorphism in the susceptibility to develop PF and PAH in SSc patients.  
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MATERIALS AND METHODS 
Samples 
Overall, 4,392 SSc patients and 16,591 unaffected controls from Spain, Germany, The 
Netherlands, Italy, the United Kingdom, and Norway were included in the present study. The 
cohorts included in this study were partially overlapping with the cohorts in Bossini-Castillo et 
al. [7], based on the presence of pulmonary involvement clinical data. In total, the overlap 
between our global study cohort and the one included in [7] was 30%.All patients were 
classified as having dcSSc or lcSSc, following the criteria described by LeRoy et al. [14]. Patients 
were additionally classified accordingly with the presence or absence of ACA and ATA 
antibodies. PF was diagnosed by the presence of interstitial abnormalities in high-resolution 
computed tomography (HRCT) and force vital capacity (FVC) lower than 60%. Pulmonary 
hypertension was considered PAH if FVC was higher than 60 % or there was not moderate-
severe extent of interstitial lung disease in HRCT. Thus, patients were defined as PAH+ if they 
showed a mean resting pulmonary artery pressure ≥ 25 mmHg, at the time of a right heart 
catheterization, pulmonary artery wedge pressure (PAWP)≤15 mmHg and FVC > 60% [15, 16]. 
The control population consisted of unrelated healthy individuals recruited in the same 
geographic regions as the SSc patients.  
The local ethical committees from all the contributing centers approved the project in 
compliance with the Helsinki Agreement (Valle de Hebron Hospital, 12 de Octubre University 
Hospital, San Cecilio University Hospital, de la Santa Creui Sant Pau Hospital, Carlos Haya 
Hospital, San Carlos Hospital, Bellvitge University Hospital, Virgen del Rocio Hospital, San Jorge 
General Hospital, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinic Foundation, degli 
Studi di Verona University, Spedali Civili Hospital, Oslo University Hospital, Josefs-Hospital, 
University of Lübeck, Hannover Medical School, University of Cologne, Radboud University 
Nijmegen Medical Centre, VU University Medical Center, Leiden University Medical Center, 
Glasgow Biomedical Research Centre, Manchester University, University Medical Center 
MIF in Scleroderma-PAH 
 
7 
Utrecht). Patients and controls gave written informed consent for their participation in the 
present study. 
Genotyping  
DNA extraction was performed using standard methods. MIF rs755622 was genotyped 
using a TaqMan® SNP genotyping assay (assay ID: C_2213785_10) in a Light Cycler 480 Real-
Time PCR System (Roche Applied Science, Mannheim, Germany). We also used available MIF 
rs755622  genotyping data from a previously published study based on the Immunochip [17], a 
genotyping platform that was specifically designed for the study of the genetic component of 
immune-mediated diseases. Supplementary Table 1 shows the number of samples genotyped 
in each platform. The genotyping call rate (the fraction of called samples per SNP over the total 
number of samples in the dataset) was 97% for the TaqMan assay and 99% for the 
Immunochip data. The genotype–genotype concordance was evaluated in 1,253 samples with 
genotyping data from both platforms. A 100% of concordance was observed between both 
genotyping platforms. 
Statistical methods 
Using the Power Calculator for Association Studies (CaTS) software 2006 (Center for 
Statistical Genetics, The University of Michigan, USA), and assuming an effect size of OR=1.2, 
we estimated that the statistical power of the study was 99% for the overall analysis of the 
whole cohort (SSc cases vs. controls), 98% for the analysis of dcSSc and PF phenotypes, 61% for 
the analysis of PAH+ patients and 5% for the analysis with dcSSc patients that have PAH. Since 
the statistical power depends on the odd ratio (OR) of the SNP, we also calculated the 
statistical power for this last comparison assuming the observed effect size in this study, 
obtaining a 97% of statistical power. Additionally, no deviation from Hardy-Weinberg 
equilibrium was detected in our datasets. 
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All the statistical analyses were carried out with PLINK v1.07 
(http://pngu.mgh.harvard.edu/purcell/plink/). Association statistics for the six cohorts were 
calculated in each population by 2x2 contingency tables and χ2 test. P-values lower than 0.05 
were considered as statistically significant. The inverse variance weighted fixed-effects meta-
analysis method was used for the pooled analyses.   
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RESULTS 
We first investigated whether there were significant differences between the rs755622 
allele frequencies of the whole SSc group or the different stratified groups (by 
clinical/autoantibody phenotypes) and those of the control set. Supplementary Table 2 
summarizes the results for the analyses of the independent cohorts and Table 1 shows the 
results of the pooled analysis. As observed in Table 1, a significant P-value was obtained when 
the dcSSc group was compared against the control set in the meta-analysis (P=3.20E-2, 
OR=1.13, 95% CI=1.01-1.26). Moreover, there was a significant increase of the minor allele 
frequency in the group of SSc patients affected by PAH compared to controls (P=2.19E-02, 
OR=1.32, 95% CI=1.04-1.67). However, no association was observed between rs755622 and 
the PF-positive SSc group (PF+ vs. controls: P=0.257, PF+ vs PF-:P=0.737). 
In order to dissect out the genetic association of rs755622*C with the SSc clinical 
phenotypes, we classified the patients into four additional subgroups based on the SSc subtype 
and the presence/absence of PAH. Then, we carried out a pooled analysis of the six cohorts by 
comparing these new subsets against controls (Table 2; see Supplementary Table 3 for the 
results of each cohort independently). A considerably significant difference in the rs755622 
frequencies between controls and the subgroup of patients with both dcSSc and PAH 
phenotypes was observed (dcSSc with PAH vs. controls: P=6.91E-03, OR=2.05, 95% CI= 1.30-
4.05).However, no association was evident in the analysis of the other subgroups against 
controls (lcSSc with PAH vs. controls: P=0.178; dcSSc without PAH vs. controls: P=0.083; lcSSc 
without PAH vs. controls: P=0.436). We also did not find evidence of association between MIF 
rs755622 and SSc-related PF and dcSSc-related PF (data not shown). 
DISCUSSION 
This study, which comprises the largest cohort of SSc-associated PAH patients analyzed to 
date, clearly suggests that the MIF rs755622*C variant is a firm genetic risk factor for the 
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susceptibility to PAH in dcSSc patients. Previous reports described an association of this SNP 
with the diffuse form of the disease [7,8]. Consistent with this, we also observed a significant 
increase in the MIF rs755622*C frequency in the dcSSc subgroup compared to the control set. 
However, subphenotype analyses indicated that the significant associations detected in dSSc 
and the PAH+ subgroups may rely on the presence of subjects with both phenotypes in each 
dataset. Therefore, those carrying the MIF rs755622*C allele are at a higher risk of suffering 
dcSSc with PAH rather than PAH or dcSSc independently. The fact that the strongest effect size 
of MIF rs755622*C was observed in the subset of patients having both dcSSc and PAH (OR = 
2.05) clearly supports this idea. Therefore, our findings may suggest MIF rs755622*C as a 
marker for dSSc patients at risk of developing PAH.  
In our set, the percentages of PAH in the different phenotype subsets, dSSc or lSSc, were 
2.55 % and 6.41% respectively. This is, 14.78% of PAH+ cases were dSSc patients and 85.22% 
corresponded to lSSc cases, in line with previous reports in SSc patient cohorts [18, 19]. 
However, as mentioned above, we only found that the association observed between MIF 
rs755622 and the PAH+ group remained significant only under a dcSSc phenotype. In this 
regard, gene expression patterns specific for SSc, SSc-related PF and SSc-related PAH have 
been recently described [20], thus indicating that each SSc phenotype may be develop under a 
distinct molecular environment. The high specificity of the MIF rs755622 association with a 
particular subset of SSc patients may be related to this fact. 
MIF rs755622 is a promoter polymorphism that has been linked to the up regulation of the 
MIF expression in immune-mediated diseases [5]. As we mentioned before, this SNP is in high 
LD with the functional CATT5-8 polymorphism, and it is not still established whether rs755622 
influences MIF promoter activity by itself or whether the observed effect may be linkage to 
CATT5-8. Interestingly, elevated protein levels of this gene have been detected in the sera of 
dcSSc patients affected by PAH [13, 21]. Moreover, Le Hiress et al. showed through in vitro 
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studies that MIF receptor (CD74) is overexpressed in individuals with idiopathic PAH [22]. 
These authors also provided evidence for the effect of a MIF antagonist and anti-CD74 
neutralizing antibodies on the reversion of PH in a rat model [22].MIF is a pleotropic protein 
expressed in several human cell types that can act as a cytokine, hormonal and immune 
modulatory factor. As a cytokine, MIF induces the expression and secretion of several immune 
mediators, including interleukin-6 (IL-6) [23]. Increased levels of IL-6 have been described in 
serum and lungs of idiopathic PAH patients and those with dcSSc compared to lcSSc [24,25], 
and IL-6 has a proved effect on the generation and development of PAH in vivo [24]. Moreover, 
allelic combinations of SNPs in the IL-6 gene have been suggested as susceptibility factors for 
SSc [26]. Based on the above, we speculate that MIF rs755622 could be influencing PAH 
development in dcSSc affected individuals by promoting IL-6 secretion, which could contribute 
to the obstruction of small pulmonary vessels that leads to hypoxia and, eventually, to PAH. 
In conclusion, here we provide novel insights into the genetic background of SSc-related 
PAH. We have shown that the MIF allele rs755622*C is associated with higher risk of being 
affected by this severe condition in dcSSc patients, and our results may be helpful for a better 
evaluation of the prognosis in SSc and for the development of more effective personalized 
treatments. 
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